Amphiphilic curcumin conjugate-forming nanoparticles as anticancer prodrug and drug carriers: in vitro and in vivo effects

Bibliography

• 1  Jagtap S, Meganathan K, Wagh V, Winkler J, Hescheler J, Sachinidis A: Chemoprotective mechanism of the natural compounds, epigallocatechin-3-O-gallate, quercetin and curcumin against cancer and cardiovascular diseases. Curr. Med. Chem.16,1451–1462 (2009).
  Medline CASGoogle Scholar
• 2  Aggarwal BB, Surh YH, Shishodia S: The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease. Springer, NY, USA (2007).
  Google Scholar
• 3  Strimpakos AS, Sharma RA: Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid. Redox Signaling10,511–546 (2008).
  Medline CASGoogle Scholar
• 4  Lin YG, Kunnumakkara AB, Nair A et al.: Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-κB pathway. Clin. Cancer Res.13,3423–3430 (2007).
  Medline CASGoogle Scholar
• 5  Kunnumakkara AB, Anand P, Aggarwal BB: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett.269199–225 (2008).
  Medline CASGoogle Scholar
• 6  Karunagaran D, Rashmi R, Kumar TR: Induction of apoptosis by curcumin and its implications for cancer therapy. Curr. Cancer Drug Target5,117–129 (2005).
  Medline CASGoogle Scholar
• 7  Rajesh LT, Anuj S, Radha KM: Multiple molecular targets in cancer chemoprevention by curcumin. AAPS J.8,E443–E449 (2006).
  MedlineGoogle Scholar
• 8  Shukla S, Zaher H, Hartz A, Bauer B, Ware JA, Ambudkar SV: Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm. Res.26,480–487 (2009).
  Medline CASGoogle Scholar
• 9  Zhang W, Tan TMC, Lim L-Y: Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats. Drug Metab. Dispos.35,110–115 (2006).
  Medline CASGoogle Scholar
• 10  Li L, Ahmed B, Mehta K, Kurzrock R: Liposomal curcumin with and without oxaliplat, effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol. Cancer Ther.6,1276–1282 (2007).
  Medline CASGoogle Scholar
• 11  Dorai T, Cao YC, Dorai B, Buttyan R, Katz AE: Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate47293–303 (2001).
  Medline CASGoogle Scholar
• 12  Somers-Edgar TJ, Scandlyn MJ, Stuart EC, Le Nedelec MJ, Valentine SP, Rosengren RJ: The combination of epigallocatechin gallate and curcumin suppresses ERα -breast cancer cell growth in vitro and in vivo. Int. J. Cancer122,1966–1971 (2008).
  Medline CASGoogle Scholar
• 13  Narayanan Narayanan K, Nargi D, Randolph C, Narayanan Bhagavathi A: Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int. J. Cancer125,1–8 (2009).
  Medline CASGoogle Scholar
• 14  Milacic V, Banerjee S, Landis-Piwowar KR, Sarkar FH, Majumdar APN, Dou QP: Curcumin Inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res.68,7283–7292 (2008).
  Medline CASGoogle Scholar
• 15  Dujic J, Kippenberger S, Ramirez-Bosca A et al.: Curcumin in combination with visible light inhibits tumor growth in a xenograft tumor model. Int. J. Cancer124,1422–1428 (2009).
  Medline CASGoogle Scholar
• 16  William BM, Goodrich A, Peng C, Li S: Curcumin inhibits proliferation and induces apoptosis of leukemic cells expressing wild-type or T315I-BCR-ABL and prolongs survival of mice with acute lymphoblastic leukemia. Hematology13,333–343 (2008).
  Medline CASGoogle Scholar
• 17  Purkayastha S, Berlinerb A, Fernandoa SS et al.: Curcumin blocks brain tumor formation. Brain Res.1266,130–138 (2009).
  Medline CASGoogle Scholar
• 18  Shankar S, Ganapathy S, Chen Q, Srivastava RK: Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol. Cancer7,16 (2008).
  MedlineGoogle Scholar
• 19  Ajaikumar BK, Preetha A, Bharat BA: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett.269199–225 (2008).
  MedlineGoogle Scholar
• 20  Chen H-W, Lee J-Y, Huang J-Y et al.: Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1. Cancer Res.68,7428–7438 (2008).
  Medline CASGoogle Scholar
• 21  Narasimhan M, Ammanamanchi S: Curcumin blocks RON tyrosine kinase-mediated invasion of breast carcinoma cells. Cancer Res.68,5185–5192 (2008).
  Medline CASGoogle Scholar
• 22  Kunnumakkara AB, Diagaradjane P, Guha S et al.: Curcumin sensitizes human colorectal cancer xenografts in nude mice to γ-radiation by targeting nuclear factor-κB-regulated gene products. Clin. Cancer Res.14,2128–2136 (2008).
  Medline CASGoogle Scholar
• 23  Javvadi P, Segan a T, Tuttle SW, Koumenis C: The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. Mol. Pharmacol.73,1491–1501 (2008).
  Medline CASGoogle Scholar
• 24  Kunnumakkara a B, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB: Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-κB-regulated gene products. Cancer Res.67,3853–3861 (2007).
  Medline CASGoogle Scholar
• 25  Kamat AM, Sethi G, Aggarwal BB: Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through downregulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in IFN-α -sensitive and IFN-α -resistant human bladder cancer cells. Mol. Cancer Ther.6,1022–1030 (2007).
  Medline CASGoogle Scholar
• 26  Cheng AL, Hsu CH, Lin JK et al.: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. AntiCancer Res.21,2895–2900 (2001).
  Medline CASGoogle Scholar
• 27  Sharma R A, Euden SA, Platton S L et al.: Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res.10,6847–6854 (2004).
  Medline CASGoogle Scholar
• 28  Dhillon N, Aggarwal BB, Newman RA et al.: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res.14,4491–4499 (2008).
  Medline CASGoogle Scholar
• 29  Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB: Bioavailability of curcumin: problems and promises. Mol. Pharm.4,807–818 (2007).
  Medline CASGoogle Scholar
• 30  Wang Y-J, Pan M-H, Cheng A-L et al.: Stability of curcumin in buffer solutions and characterization of its degradation products. J. Pharm. Biomed. Anal.15,1867–1876 (1997).
  Medline CASGoogle Scholar
• 31  Liang G, Shao L, Wang Y et al.: Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg. Med. Chem.17,2623–2631 (2009).
  Medline CASGoogle Scholar
• 32  Youssef D, Nichols CE, Cameron TS, Balzarini J, De Clercq E, Jha A: Design, synthesis, and cytostatic activity of novel cyclic curcumin analogues. Bioorg. Med. Chem. Lett.17,5624–5629 (2007).
  Medline CASGoogle Scholar
• 33  Chen C, Johnston TD, Jeon H et al.: An in vitro study of liposomal curcumin: stability, toxicity and biological activity in human lymphocytes and Epstein–Barr virus-transformed human B-cells. Int. J. Pharm.366,133–139 (2009).
  Medline CASGoogle Scholar
• 34  Shankeshi J, Aukunuru J: Preparation, characterization and evaluation of antidiabetic activity of a liposomal formulation encapsulating curcumin, an ayurvedic natural product. Pharmacist (Bhopal, India)3,1–5 (2008).
  CASGoogle Scholar
• 35  Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward W P, Gescher a J: Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother. Pharmacol.60,171–177 (2007).
  Medline CASGoogle Scholar
• 36  Bisht S, Feldmann G, Soni S et al.: Polymeric nanoparticle-encapsulated curcumin (“nanocurcumin”): a novel strategy for human cancer therapy. J. Nanobiotechnol.5,1–18 (2007).
  MedlineGoogle Scholar
• 37  Shi W, Dolai S, Rizk S et al.: Synthesis of monofunctional curcumin derivatives, clicked curcumin dimer, and a PAMAM dendrimer curcumin conjugate for therapeutic applications. Org Lett.9,5461–5464 (2007).
  Medline CASGoogle Scholar
• 38  Safavy A, Raisch KP, Mantena S et al.: Design and development of water-soluble curcumin conjugates as potential anticancer agents. J. Med. Chem.50,6284–6288 (2007).
  Medline CASGoogle Scholar
• 39  Maeda H, Wu J, Sawa T, Matsumura Y, Hori K: Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release65,271–284 (2000).
  Medline CASGoogle Scholar
• 40  Meister A, Anderson M: Glutathione. Ann. Rev. Biochem.52,711–760 (1983).
  Medline CASGoogle Scholar
• 41  Huggins C, Moulton S: Esterases of testis and other tissues. J. Exp. Med.88,169–179 (1948).
  Medline CASGoogle Scholar
• 42  Fu M, Wang C, Li Z, Sakamaki T, Pestell RG: Cyclin D1: normal and abnormal functions. Endocrinology145,5439–5447 (2004).
  Medline CASGoogle Scholar
• 43  Hengstschlager M, Braun K, Soucek T, Miloloza A, Hengstschlager-Ottnad E: Cyclin-dependent kinases at the G1-S transition of the mammalian cell cycle. Mut. Res.436,1–9 (1999).
  Medline CASGoogle Scholar
• 44  Ravindranath V, Chandrasekhara N: Absorption and tissue distribution of curcumin in rats. Toxicology16,259–265 (1980).
  Medline CASGoogle Scholar
• 45  Pan M H, Huang T M, Lin JK: Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab. Dispos.27,486–494 (1999).
  Medline CASGoogle Scholar
• 46  Ireson C, Orr S, Jones DJL et al.: Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res.61,1058–1064 (2001).
  Medline CASGoogle Scholar
• 47  Yang KY, Lin LC, Tseng TY, Wang SC, Tsai TH: Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J. Chromatogr. B Anal. Technol. Biomed. Life Sci.853,183–189 (2007).
  CASGoogle Scholar
• 48  Lock R, Debnath J: Extracellular matrix regulation of autophagy. Curr. Opin. Cell Biol.20,583–588 (2008).
  Medline CASGoogle Scholar
• 49  Aoki H, Takada Y, Kondo S, Sawaya R, Aggarwal BB, Kondo Y: Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol. Pharmacol.72,29–39 (2007).
  Medline CASGoogle Scholar
• 50  Wong H, Bendayan R, Rauth A, Xue H, Babakhanian K, Wu X: A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J. Pharmacol. Exp. Thera.317,1372–1381 (2006).
  Medline CASGoogle Scholar